Menorrhagia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Menorrhagia Market Outlook

Thelansis’s “Menorrhagia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Menorrhagia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Menorrhagia Overview

Menorrhagia, also recognized as heavy menstrual bleeding, significantly hampers regular activities, impacts quality of life, and induces anemia in approximately two-thirds of women experiencing objective Menorrhagia (defined as a loss of 80 mL blood per cycle). Termed abnormal uterine bleeding for precision, Menorrhagia can be categorized into nine groups under the PALM-COEIN acronym:

1. Polyp
2. Adenomyosis
3. Leiomyoma
4. Malignancy and hyperplasia
5. Coagulopathy
6. Ovulatory dysfunction stemming from conditions like hypothyroidism, hyperthyroidism, prolactin-secreting tumors, or PCOS
7. Endometrial factors
8. Iatrogenic causes, such as the use of IUDs, chemotherapeutic agents, or anticoagulants
9. Unclassified origins

The pathophysiology of abnormal uterine bleeding (AUB) mirrors the diversity encapsulated by its classification. AUB can arise from pelvic anomalies like distortion of the endometrial cavity due to fibroids, endometrial protrusions into the cervix or vagina (polyps), or friable endometrial tissue. Additionally, certain medications can lead to AUB, including but not limited to:

• Warfarin, aspirin, clopidogrel, and other anticoagulants
• Contraceptive medications and devices
• Tamoxifen
• Tricyclic antidepressants
• Antipsychotics
• Corticosteroids

The primary treatments for Menorrhagia associated with ovulatory cycles, considered first-line options, are nonhormonal in nature: namely, the antifibrinolytic tranexamic acid and nonsteroidal anti-inflammatory drugs.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: